Diagnostic approach to the patient with cardiomyopathy: whom to biopsy
Hossein Ardehali1, Edward K Kasper, Kenneth L Baughman
1Division of Cardiology, Department of Medicine, Johns Hopkins University, Baltimore, Md, USA.
Insights
Endomyocardial biopsy (EMBx) can diagnose unknown causes of cardiomyopathy, a leading factor in heart failure. Despite past uncertainty, EMBx is a valuable tool for guiding treatment and improving patient outcomes.
Area of Science:
- Cardiology
- Pathology
Background:
- Congestive heart failure (CHF) prevalence is rising, with cardiomyopathy as a primary cause and frequent indication for heart transplantation.
- Identifying the specific cause of cardiomyopathy is crucial for prognosis and effective treatment strategies.
- Standard diagnostic methods like physical exams, echocardiograms, and angiography may not always determine cardiomyopathy etiology.
Purpose of the Study:
- To evaluate the diagnostic utility of endomyocardial biopsy (EMBx) in patients with unexplained cardiomyopathy.
- To determine if EMBx can identify specific etiologies that guide targeted therapies.
- To reassess the role of EMBx in the workup of heart failure patients with unclear cardiomyopathy causes.
Main Methods:
- Review of clinical data and endomyocardial biopsy (EMBx) results in patients with cardiomyopathy of unknown origin.
- Comparison of diagnostic yield of EMBx versus initial non-invasive evaluations.
- Analysis of treatment implications and patient outcomes following EMBx findings.
Main Results:
- While initial evaluations often fail to identify cardiomyopathy causes, EMBx can provide definitive etiological diagnoses.
- Despite historical skepticism stemming from trials like the Myocarditis Treatment Trial, recent evidence supports EMBx's value.
- EMBx findings can potentially guide specific treatments, although the direct impact on left ventricular function improvement requires further study.
Conclusions:
- Endomyocardial biopsy (EMBx) remains a valuable diagnostic tool for patients with cardiomyopathy where the etiology is not identified by standard investigations.
- The indications for EMBx in unexplained cardiomyopathy should be reconsidered, as it offers potential for etiological diagnosis and tailored therapeutic approaches.
- Further research is warranted to fully elucidate the prognostic and therapeutic benefits of EMBx-guided management in heart failure patients.
Abstract:
The prevalence of congestive heart failure is increasing and the prognosis remains poor. Cardiomyopathy is one of the most frequent causes of congestive heart failure and is the most common etiology of patients submitted to heart transplant. Determination of the etiology of cardiomyopathy has both prognostic and therapeutic implications. History, physical examination, transthoracic echocardiogram, selected laboratory studies, and coronary angiography can often define the cause of cardiomyopathy, however, the etiology occasionally remains unknown despite this initial evaluation. The indications for endomyocardial biopsy (EMBx) in patients with cardiomyopathy and a negative initial evaluation remains uncertain. The search for Dallas histological criteria proven myocarditis prompted the performance of EMBx in patients with unexplained cardiomyopathy in hopes of identifying an etiology for which treatment would result in improvement in left ventricular function. The "negative" results of the Myocarditis Treatment Trial, with treated and controlled patients improving equally, dampened enthusiasm for this diagnostic procedure. However, our experience and recent evidence suggests that EMBx may be a valuable diagnostic modality and should be included in the evaluation of patients with initially unexplained cardiomyopathy.
Related Concept Videos
01:27Myocarditis II: Clinical Features and Diagnostic Tests
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:30Dysrhythmias V: Evaluating Dysrhythmias